ICU patients where physician decision to administer furosemide for fluid management Diuretics, Furosemide, Water-Electrolyte Balance, Intensive Care Units
Conditions
Interventions
Adjunctive acetazolamide arm: patients will receive adjunctive acetazolamide over 48hours of enrolment
In this interventional arm, patients will receive 500mg of acetazolamide simultaneously or within
Acetazolamide, Diuretics, Furosemide
Sponsors
Doi Kent
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Adults aged > 18 years Physician decision to administer furosemide for fluid management Anticipated ICU stay for three consecutive days from enrolment Existing intra-arterial or central venous catheter Existing indwelling urinary catheter
Exclusion criteria
Exclusion criteria: Known allergy to furosemide or acetazolamide or other sulphonamides Baseline eGFR 7.5 and BE > +5) Acute liver failure or high risk for hyperammonemia Prior renal replacement therapy during this ICU admission Confirmed or suspected pregnancy or breast-feeding Previous enrolment in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure is the mean difference in Base Excess over 48 hours of enrolment between arms. | — |
Secondary
| Measure | Time frame |
|---|---|
| The mean difference in serum pH over 48 hours of enrolment. The mean difference in serum electrolyte levels (Na, K, Cl) over 48 hours. Change in P/F ratio over 48 hours of enrolment. Overall urine output/fluid balance in 24 hours of enrolment. Overall urine output/fluid balance in 48 hours of enrolment. The mean difference in the total dose of furosemide over 48 hours. The mean difference in the urine output response to furosemide (ml/mg/hour) over 48 hours. MAKE 30 (censored at hospital discharge). MAKE30 is defined as a composition of death within 30 days of enrolment, RRT dependence (defined as any RRT use in the preceding three days of assessment), or PRD (defined as a final creatinine value greater than or equal to 200% of the baseline value). Vasopressor-free days at day 7. ICU and hospital length of stay after enrolment (days). Ventilator-free days at 30 days. 30-day mortality. Number of patients who develop severe acidosis (pH <7.25) or hypokalemia (K <2.5) within 48 hours. | — |
Countries
Australia, Japan
Contacts
Public ContactAkinori Maeda
The University of Tokyo Hospital
Outcome results
None listed